| Autor: |
Pantoja MV; Department of Internal Medicine, Universidad Simón Bolívar, Barranquilla, Colombia., Lozada-Martinez ID; Biomedical Scientometrics and Evidence-Based Research Unit, Department of Health Sciences, Universidad de la Costa, Barranquilla, Colombia. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of preventive medicine and public health = Yebang Uihakhoe chi [J Prev Med Public Health] 2024 Sep; Vol. 57 (5), pp. 508-510. Date of Electronic Publication: 2024 Sep 27. |
| DOI: |
10.3961/jpmph.24.364 |
| Abstrakt: |
Population aging is a global health priority due to the dramatic increase in the proportion of older persons worldwide. It is also expected that both global life expectancy and disability-free life expectancy will increase, leading to a significant rise in the proportion of individuals with extreme longevity, such as non-agenarians and centenarians. The inaccuracy of clinical evidence on therapeutic interventions for this demographic could lead to biased decision-making, influenced by age-related beliefs or misperceptions about their therapeutic needs. This represents a potential clinical ageism scenario stemming from gaps in clinical evidence. Such biases can result in 2 significant issues that adversely affect the health status and prognosis of older persons: polypharmacy and therapeutic inertia. To date, documents on polypharmacy in non-agenarians and centenarians account for less than 0.35% of the overall available evidence on polypharmacy. Furthermore, evidence regarding therapeutic inertia is non-existent. The purpose of this letter is to discuss polypharmacy and therapeutic inertia as potential clinical ageism scenarios resulting from the clinical evidence gaps in extreme longevity. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
